Barrow Robert's Form 4 filing
Definium Therapeutics, Inc. (DFTX) · filed Dec 27, 2024
- Accession no.
- 0001104659-24-132167
- Filed
- Dec 27, 2024
- Trade date
- Dec 26, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $142.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Barrow RobertCIK 0001897557 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2024 | Common Shares | SSaleDisposed | −19,106 | $7.43F2 | −$141,957.58 | 526,666 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.